# Corcept Therapeutics Inc. (CORT)

> Corcept Therapeutics Inc. (CORT) trades at $72.94 (-1.04%) as of 7:55:10 PM EST on Nov 13, 2026, -35.66% over the past month. Market cap is $7.97B, with 8.1 days to cover in short interest.

Canonical: https://massive.com/quote/cort
Data as of: 2026-11-14T00:55:10.422Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$72.94** -0.77 (-1.04%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$76.77** +3.83 (+5.25%)
As of 7:55:10 PM EST on Nov 13, 2026 · After hours

## Stock performance

How Corcept Therapeutics Inc. (CORT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.04% |
| 1W | +0.23% |
| 1M | -35.66% |
| YTD | +109.60% |
| 1Y | -2.90% |
| 52-wk range | $28.66 – $126.38 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for CORT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $71.18 – $74.68 |
| Open | $73.87 |
| Prev close | $73.71 |
| Volume | 1.11M |
| Market cap | $7.97B |
| Shares out | 109.44M |

## Valuation and profitability ratios

Valuation and profitability ratios for Corcept Therapeutics Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 48.70 |
| P/S | 8.18 |
| P/B | 9.46 |
| P/FCF | 40.51 |
| ROE | 19.4% |
| ROA | 15.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[Corcept Therapeutics Inc. (CORT) insider trading](https://massive.com/quote/cort/insider-trading.md): open-market Form 4 buys and sells by Corcept Therapeutics Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Corcept Therapeutics Inc. has disclosed to the SEC on Form 8-K.

- Nov 3, 2026 · Business update
  “On November 3, 2026, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026 and a corporate update.”
- Sep 23, 2026 · Executive compensation change
  “In connection with Mr. Maduck's resignation, the Company and Mr. Maduck entered into a Consulting Services Agreement ... pursuant to which Mr. Maduck will provide consulting services to the Company's Chief Executive Officer and executive management team. ... Mr. Maduck will be paid a cash fee of $57,000 per month. The Agreement further provides that during Mr. Maduck's consulting term with the Company, Mr. Maduck's previously awarded and currently outstanding stock options shall continue to vest according to the original vesting schedule of each such stock option.”
- Jun 3, 2026 · Regulatory investigation
  “On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United States Department of Justice (the "DOJ") had filed a Notice of Election to Decline Intervention (the "Notice") in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., No. 17-CV-1303 (SRC) (D.N.J.). That action was initiated in February 2017, in the District Court of New Jersey, by a former employee of the Company (the "Relator"). In connection with that action, the DOJ previously issued a records subpoena to the Company in November 2021, seeking information relating to the sale and promotion of Korlym®, the Company's relationships with and payments to health care professionals who prescribe or recommend Korlym, and prior authorizations and reimbursement for Korlym.”
- Mar 25, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “the U.S. Food and Drug Administration has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.”
- Feb 19, 2026 · Material litigation
  “the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals' marketing of a generic version of Korlym® does not infringe two of the Company's patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme”

## Similar companies

Public companies in a similar business to Corcept Therapeutics Inc..

- [ANVS](https://massive.com/quote/anvs.md) Annovis Bio, Inc. (+9.31%)

Daily change in the latest session, 15-minute delayed.

## CORT short interest

How heavily CORT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.1 |
| Short interest | 9.13M |
| Avg volume | 1.13M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## CORT news

The latest news and headlines about Corcept Therapeutics Inc. (CORT).

- [Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates](https://www.zacks.com/stock/news/3022258/corcept-therapeutics-cort-q3-earnings-and-revenues-surpass-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3022258) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?](https://www.zacks.com/stock/news/3010520/can-lifyorli-aid-corcept-s-long-term-growth-prospects-beyond-korlym?cid=CS-ZC-FT-analyst_blog|quick_take-3010520) · Zacks Investment Research · Oct 19, 2026 · positive sentiment
- [The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics](https://www.zacks.com/stock/news/3010333/the-zacks-analyst-blog-highlights-ross-stores-roku-apa-corcept-therapeutics-and-halozyme-therapeutics?cid=CS-ZC-FT-press_releases-3010333) · Zacks Investment Research · Oct 19, 2026 · positive sentiment
- [Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains](https://www.zacks.com/stock/news/3009125/buy-5-top-ranked-non-tech-nasdaq-stocks-to-maximize-q4-gains?cid=CS-ZC-FT-analyst_blog|investment_ideas-3009125) · Zacks Investment Research · Oct 16, 2026 · positive sentiment
- [3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge](https://www.zacks.com/stock/news/3008883/3-low-beta-defensive-stocks-to-buy-as-inflation-continues-to-surge?cid=CS-ZC-FT-analyst_blog|investment_ideas-3008883) · Zacks Investment Research · Oct 15, 2026 · positive sentiment

## About Corcept Therapeutics Inc.

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 730 |
| Listed | Apr 14, 2004 |

[Company website](https://www.corcept.com)

## FAQ

### What is the Corcept Therapeutics Inc. (CORT) stock price today?

Corcept Therapeutics Inc. (CORT) is trading at $72.94 (-1.04% on the day) as of 7:55:10 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Corcept Therapeutics Inc.?

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.

### What is the short interest in CORT?

As of Oct 30, 2026, CORT has 9.13M shares short and 8.1 days to cover.

### What exchange is CORT listed on?

Corcept Therapeutics Inc. (CORT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time CORT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=CORT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Corcept Therapeutics Inc. (CORT) insider trading](https://massive.com/quote/cort/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
